Inhibitory T Cell Receptor Peptides and Discovery Methods

USPTO granted patent US12606816B2 to Janux Therapeutics, Inc. for inhibitory T cell receptor peptides and associated discovery methods. The patent covers peptides that bind directly to T cell receptors to inhibit interactions with peptide-major histocompatibility complexes, as well as methods for identifying such inhibitory peptides.

For parties engaged in T cell receptor research or immunotherapy development, this patent establishes intellectual property protection for Janux in this specific technological space. Researchers and companies in related fields should consider potential freedom-to-operate implications when developing similar peptide-based T cell receptor modulators.